Search
Now showing items 1-7 of 7
Validation of the electronic Psoriasis Area and Severity Index application : Establishing measurement equivalence
(2019-12-01)
To the Editor: Despite its many shortcomings, the Psoriasis Area and Severity Index (PASI) remains the standard method worldwide for psoriasis assessment.1 Several studies have implemented electronic versions without ...
Presenting signs and patient co-variables in Gaucher disease : outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative
(2019-05-01)
Background: Gaucher disease (GD) presents with a range of signs and symptoms. Physicians can fail to recognise the early stages of GD owing to a lack of disease awareness, which can lead to significant diagnostic delays ...
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.
(2019-04-30)
Aim:To determine measurement equivalence of paper and electronic application of the hematologi-cal malignancy-patient-reported outcome (HM-PRO), a specific measure for the evaluation of patient-reported outcomes in ...
Factors influencing delays in patient access to new medicines in Canada: a retrospective study of reimbursement processes in public drug plans
(2019-03-29)
Individuals who rely on public health payers to access new medicines can access fewer innovative medicines and must wait longer in Canada compared to major markets around the world. New medicines/indications approved by ...
The South African Medicines Control Council: Comparison of Its Registration Process With Australia, Canada, Singapore, and Switzerland
(2019-03-14)
Introduction: Comparisons between regulatory authorities of similar size and regulatory characteristics facilitate value-added benchmarking and provide insight into regulatory performance. Such comparisons highlight areas ...
Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications
(2019-02-18)
This analysis follows our recent study showing that Canadian public reimbursement delays have lengthened from regulatory approval to listing decisions by public drug plans and delayed public access to innovative medicines, ...
Validation of the Thai version of the family reported outcome measure (FROM-16)© to assess the impact of disease on the partner or family members of patients with cancer
(2019-02-08)
Background: Cancer not only impairs a patient's physical and psychosocial functional behaviour, but also contributes to negative impact on family members' health related quality of life. Currently, there is an absence of ...